DOCSLIB.ORG

Benzodiazepines, the Story of the Antagonist Flumazenil and of the Partial Agonist Bretazenil

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Benzodiazepines, the Story of the Antagonist Flumazenil and of the Partial Agonist Bretazenil FORSCHUNG 141 (,HIMIA 47 (1993) Nr." (Mai) Chim;a 47 (/993) 141-/47 © Neue SchIVeizerische Chemische Gesellscllllft /SSN 0009-4293 Benzodiazepines, the Story of the Antagonist Flumazenil and of the Partial Agonist Bretazenil Walter Hunkeler: Born 1938 in Altishofen. Walter Hunkeler* Lucerne. 1955-58 apprenticeship as laborato- ry assistentatS;egfr;edAG inZofingen. 1960- 63 study of chemistry at the Institute of Tech- nology of the State of Berne. Burgdorf. and Abstract. The story offlumazenil and bretazenil is a typical example of a serendipitious 1965-69 at the University of Berne. Doctoral drug discovery. In 1979 benzodiazepine antagonists were unknown. No one was thesis under the direction of Prof. H. Sclwlteg- looking for them, but they were discovered nevertheless. Ro 15-1788 was selected for ger. Postdoctoral research at the ETH-Zurich with Prof. A. Eschenmoser. Since 1974 at F. clinical trial. Today 'this compound has the generic name f1umazenil, the trade name Hoffmann-La Roche AG in Basel. Anexate, and is registered in 70 countries. Itis the first specific benzodiazepine receptor antagonist for clinical use. Minor structural modifications of benzodiazepine antago- nists led to partial agonists, compounds with powerful anxiolytic and anticonvulsant properties. Compared with full agonists they have markedly reduced sedative and alcohol-potentiating effects. Bretazenil is in clinical trial; it exhibits promising anxio- other stems from the triazolobenzo-di- lytic activity especially in patients with panic attacks. In open clinical studies it has azepines, which were synthesized and in- shown remarkable antipsychotic activity. Structure-activity relationships and spin-offs vestigated at about the same time at Take- are discussed. da Chemical Industries in Japan and at the Upjohn Company in the United States [4][5]. These are more potent than previ- 1. The Chemical Pedigree of know this, when they started synthesizing ous benzodiazepines. FlumazeniJ (20) simpler analogues of anthramycin, since Alprazolam (4), to take one example, the existence of the BZR had not yet been is more potent in terms of anticonvulsant Chlordiazepoxide (1, Librium) is the established. A numberoftheir compounds and anxiolytic effects. The question that first anxiolytic with the structure of a showed some anticonvulsant and anti-con- now arose was whether annelation by a benzodiazepine. It was synthesized in 1955 flict activity in animal tests. Thus, 5 was tri azo I0 ring would also work in a different and submitted for testing by Leo H. Stern- selected as a candidate for anxiolytic eval- series, e.g., with the Lederle anthramycin bach in 1957 at F. Hofjinann-La Roche, uation in a limited clinical trial in man, but derivative? Would this result in a more Nutley, USA [1]. The time elapsing be- it failed to produce sufficient anxiolytic potent substance? Compound 6 was syn- tween the first pharmacological testing activity. Their results were published [3]. thesized to answer these questions: and introduction on the market was only This is one branch of the pedigree; the In December 1978, the two imida- two and a half years. In 1963, diazepam (2, Valium), the best known and best investi- gated benzodiazepine reached the market place. At this time, when benzodiazepines \ 0 YN'N were a major focus of attention in Nutley, ,~i:-" o~o one group there, Leimgruber, Batcho, and "y Schenker was working on antibiotics. They ~ /, ~ /, ~y;) CIM;0 " isolated anthramycin (3) and elucidated 0 0 its structure [2]. To their great surprise, Chlordiazepoxide Diazepam they discovered that it, too, was a 1,4- benzodiazepine. 0 0 Anthramycin (3) was later found to H3C N ,... , (' 0••.•.•••.••.• have no affinity for the benzodiazepine y " A receptor (BZR). Chemists working at Led- ~ I ~ rt"{) N erie at that time were not in a position to "1 CC;H CIM; 0 "'~~, : I ".6 ~ 0 0 CONH,o ~ ::~" 0 ~ *Correspondence: Dr. W. Hunkeler F. Hoffmann-La Roche. Ltd. Anthramycin Alprazolam PRPN ]5/235 CH-4002 Basel FORSCHUNG 142 CHIW,\ ~71IQQJ) Nr. SIMail zoesters 7 and 8 were synthesized and rine, had with 6.4 nM an even greater Table I. Billdillg Activities OfCol/1f1ol/luls submitted for testing together with the affinity for the BZR than diazepam. As a SYllthesi~ed 0/1 the Way to Fluma-;,ellil (20) triazolo compound 6. All turned out to be consequence of this preliminary result, inactive in the usual tests for benzodi- compounds without the CI-atom in the omp und Inhibition f 'II'lhu/cpam azepmes. phenyl ring were synthesized. Thus, the blllding i/ll'ifrrJ, IC'Ill' in nM Luckily for us, the benzodiazepine re- first three compounds in this new series ceptor (BZR) had been discovered the already indicated that structure-activity 9 > 1000 year before [6][7]. Usingthe3H-diazepam relationship were different from those de- binding assay it became possible to deter- termined for the older benzodiazepines, 10 > 1000 mine the affinity of a compound for the such as 2. The fact that 7 and 8, with an BZR in vitro. The three compounds were affinity for the BZR, failed to show BZ- 11 > IO{){) tested in this assay, and the triazolo deriv- like activity was not very discouraging ati ve 6 that we had favored proved to have initially, because for metabolic or phar- 12 ;> 1000 no affinity for the BZR. However, the macokinetic reasons in vitro activity is imidazo-ester 8, with a CI-atom in the often not accompanied by in vivo activity. 13 u same position as in diazepam, had an IC50 Therefore, synthetic work in the series of of 62 nM. Compound 7, without the chlo- imidazobenzodiazepinones continued. 14 . .0 0 0 0 Rapid hydrolysisoftheester7, the lead (' /'.... compound, to the inactive acid 9 was a N!J OH ~'~ Ii ° possible explanation for inactivity of 7 in vivo. The amide 10 was also inactive ill 0;,6~ I: <J 0;;,," vitro. This was surprising since the classi- 0;;" cal benzodiazepine series contains a 0 0 35 ° number of highly potent imidazo amides. The lead compound 7 is chiral and has the 9 10 11 absolute configuration (S). The (R)-enan- tiomer 11 is inactive in the BZR binding test. Compound 12, containing the six- membered ring, was inactive but the result 0 0 0 with the N-methyl compound 14 showed that this ring is not required for increased rro~ affinity for the BZR. Later on, 13 with the four-membered ring was synthesized; it ~io~I h NJ ~-rif' 0;" has a high affinity for the BZR (TaMe I). 0 0 0 A considerable number of compounds synthesized in the first hal f of 1979 had 12 13 14 very high affinity for the BZR. In spite of this, the compounds displayed no or only borderline activity in I'il'o. The possibility Scheme J that these compounds might be antago- nists was discussed. Our suspicions were CI,CCH(OH), H NH H,NOH. HCI H AcOH, H,O, increased, when further testing revealed I~ Na,SO., H,O DN~/OH"-': ""N H,SO, H,SO, 0 D ' 0 I that the lead compound 7 also bound to the F ~ I ~ 95% F 89% F~ ~ 80% receptor in vivo, demonstrating that the 0 16 15 17 target, the BZR in the brain, was reached. In early September 1979 a rat was sedated o 1. POCI" CHCI, with diazepam (2), after which it received p-CH,·C.H,N(CH,), H 0 an injection of7. Even before the injection 2 2. CNCH2C02Et CH,NHCH,C0DMF, AcOH H BC;N)I "-': KOtBu,DMF was finished the rat got up and walked off. ~ New tests were immediately devised. In 75% F N\ 78% ,~r~ each situation the effects of diazepam o o Ro 15·1788 and other benzodiazepines were reversed 18 19 flumazenil 20 ANEXATE by 7. ,. NaH, CIPO(OEt), 2 CH2(CO,EI), ~ HC(OC,Hslo 2. Optimization: Flumazenil (20) (Scheme 1) HY'COOEt 1. NaNO" AcOH ~j-COOEt The lead compound 7 was not a pure N =) NaOEt,E!OH 2.H"Pd ()"-) antagonist. Some minor agonistic activity e.g. FBC; N was found, in aconflict test in rats. We \ F~N\ o o wanted a pure antagonist for therapeutic applications and as a scientific tool. In 21 22 23 October 1979 Ro /5-1788, f1umazenil (20) FORSCHUNG 143 CHIMIA ~71Iqq.l) Nr. ~ (Mail was synthesized, and, in January 1980, selected for clinical trial. 2.1. The Synthesis of Flumazenil (20) Starting with 4-fluoroaniline (15) the isatin 17 is synthesized via the Sandmeyer synthesis; isatin is then oxidized with per- acetic acid to the isatoic anhydride 18. Reaction with sarcosine in DMF leads to 24 25 the benzodiazepine-2,5-dione 19. This is converted to the iminochloride by reac- o tion with POCI3. In the key step the imida- zoester is built up by reaction with depro- rfll 0.•...•......... tonated ethyl isocyanoacetate [8]. Since ethyl isocyanoacetate is not very stable, an CIn;N~I :::,... N alternative synthesis based on the synthe- \ sis of midazolam was developed for large o scale-production. Tnthis synthesis diethyl- 26 27 malonate is used. The diester 21 is then transformed to the monoester 22 hy deethoxycarbonylation. Nitrosation and catalytic reduction lead to the amino com- Table 2. Influence of Substitution of the Phenyl Ring 011 the Pharmacological Acti\'ity pound 23. The final carbon atom is intro- Compounu Inhlbillon or H-UI<llCpam 1'1. pl:l1l duced by reaction with the orthoester. mal! ni,m 01 dialer,lIn 1- bmdin in ritru. I Sfl in 0\1 enelelralOlc. mi c. p.o .. r.DjIJ in m~g In 1981 our paper on the first selective antagonist of benzodiazepines [9) caused enormous interest in flumazenil in the 2.7 OA scientific community.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0020892 A1 Thompson Et Al
    US 20170020892A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020892 A1 Thompson et al. (43) Pub. Date: Jan. 26, 2017 (54) USE OF NEGATIVE MODULATORS OF Related U.S. Application Data GABA RECEPTORS CONTAINING ALPHAS SUBUNITS AS FAST ACTING (60) Provisional application No. 61/972,446, filed on Mar. ANTDEPRESSANTS 31, 2014. (71) Applicant: University of Maryland, Baltimore, Publication Classification Baltimore, MD (US) (51) Int. Cl. A 6LX 3/557 (2006.01) (72) Inventors: Scott Thompson, Baltimore, MD (US); A6II 3/53 (2006.01) Mark D. Kvarta, Ellicott City, MD A6II 45/06 (2006.01) (US); Adam Van Dyke, Baltimore, MD (52) U.S. Cl. (US) CPC ........... A61 K3I/55.17 (2013.01); A61K 45/06 (2013.01); A61 K3I/53 (2013.01) (73) Assignee: University of Maryland, Baltimore, Baltimore, MD (US) (57) ABSTRACT Embodiments of the disclosure include methods and com (21) Appl. No.: 15/300,984 positions related to treatment of one or more medical conditions with one or more negative modulators of GABA (22) PCT Filed: Mar. 31, 2015 receptors. In specific embodiments, depression and/or Sui cidability is treated or ameliorated or prevented with one or (86) PCT No.: PCT/US2O15/023667 more negative modulators of GABA receptors, such as a S 371 (c)(1), partial inverse agonist of a GABA receptor comprising an (2) Date: Sep. 30, 2016 alpha5 subunit. Patent Application Publication Jan. 26, 2017. Sheet 1 of 12 US 2017/002O892 A1 ×1/ /|\ Patent Application Publication Jan. 26, 2017. Sheet 3 of 12 US 2017/002O892 A1 & Patent Application Publication Jan.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • NIH Public Access Author Manuscript Synapse
    NIH Public Access Author Manuscript Synapse. Author manuscript; available in PMC 2010 May 4. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Synapse. 2006 November ; 60(6): 411±419. doi:10.1002/syn.20314. GABAA Receptor Regulation of Voluntary Ethanol Drinking Requires PKCε Joyce Besheer, Veronique Lepoutre, Beth Mole, and Clyde W. Hodge* Bowles Center for Alcohol Studies, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 Abstract Protein kinase C (PKC) regulates a variety of neural functions, including ion channel activity, neurotransmitter release, receptor desensitization and differentiation. We have shown previously that mice lacking the ε-isoform of PKC (PKCε) self-administer 75% less ethanol and exhibit supersensitivity to acute ethanol and allosteric positive modulators of GABAA receptors when compared with wild-type controls. The purpose of the present study was to examine involvement of PKCε in GABAA receptor regulation of voluntary ethanol drinking. To address this question, PKCε null-mutant and wild-type control mice were allowed to drink ethanol (10% v/v) vs. water on a two-bottle continuous access protocol. The effects of diazepam (nonselective GABAA BZ positive modulator), zolpidem (GABAA α1 agonist), L-655,708 (BZ-sensitive GABAA α5 inverse agonist), and flumazenil (BZ antagonist) were then tested on ethanol drinking. Ethanol intake (grams/kg/day) by wild-type mice decreased significantly after diazepam or zolpidem but increased after L-655,708 administration. Flumazenil antagonized diazepam-induced reductions in ethanol drinking in wild- type mice. However, ethanol intake by PKCε null mice was not altered by any of the GABAergic compounds even though effects were seen on water drinking in these mice.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Benzodiazepine Actions Mediated by Specificg-Aminobutyric Acida
    letters to nature ..................................................................................................................................... erratum Benzodiazepine actions mediated by speci®c g-aminobutyric acidA receptor subtypes Uwe Rudolph, Florence Crestani, Dietmar Benke, Ina BruÈnig, Jack A. Benson, Jean-Marc Fritschy, James R. Martin, Horst Bluethmann & Hanns MoÈhler Nature 401, 796±800 (1999) .......................................................................................................................................................................................................................................................................... The quality of Fig. 2 was unsatisfactory as published. The ®gure is reproduced again here. M 3 3 a d [ H]Ro15-4513 [ H]Ro15-4513, Ki (nM) + diazepam 1(H101R) 1(H101R) α α Wild-type Wild-type α1 α5 Wild-type α2 β2/3 α3 γ2 1(H101R) α α b Wild-type 1(H101R) e Wild-type 3 µM GABA+Dz +Ro15 3 µM GABA α1 α1(H101R) 3 µ µ c Displacement of [ H]Ro15-4513, Ki (nM) 3 M GABA+Dz +Ro15 3 M GABA Wild-type α1(H101R) Clonazepam 3 ± 2 > 10,000 Diazepam 28 ± 15 > 10,000 Zolpidem 13 ± 5 > 10,000 500 pA 2 s ................................................................. suggest that pairing occurs primarily on the electrons on the g- correction sheet of the Fermi surface under the conditions of the experiment. However, the orientation of the FLL, interpreted within Agterberg's two-component Ginzburg±Landau (TCGL) theory1,2, is no longer consistent with g-band pairing if we take the values of Fermi surface Observation of a square ¯ux-line anisotropy used in refs 1, 2, and obtained by recent band structure calculations3. However, other calculations (T. Oguchi, private lattice in the unconventional communication) give a different sign of Fermi surface anisotropy. TCGL theory predictions may be modi®ed by extra anisotropy of superconductor Sr2RuO4 the superconducting energy gap3, by substantial pairing on the a- and/or b-sheets4 or by anisotropy in the electron mass enhance- T.
    [Show full text]
  • Radiotracers for SPECT Imaging: Current Scenario and Future Prospects
    Radiochim. Acta 100, 95–107 (2012) / DOI 10.1524/ract.2011.1891 © by Oldenbourg Wissenschaftsverlag, München Radiotracers for SPECT imaging: current scenario and future prospects By S. Adak1,∗, R. Bhalla2, K. K. Vijaya Raj1, S. Mandal1, R. Pickett2 andS.K.Luthra2 1 GE Healthcare Medical Diagnostics, John F Welch Technology Center, Bangalore, India 560066 2 GE Healthcare Medical Diagnostics, The Grove Centre, White Lion Road, Amersham, HP7 9LL, UK (Received October 4, 2010; accepted in final form July 18, 2011) Nuclear medicine / 99m-Technetium / 123-Iodine / ton emission computed tomography (SPECT or less com- Oncological imaging / Neurological imaging / monly known as SPET) and positron emission tomogra- Cardiovascular imaging phy (PET). Both techniques use radiolabeled molecules to probe molecular processes that can be visualized, quanti- fied and tracked over time, thus allowing the discrimination Summary. Single photon emission computed tomography of healthy from diseased tissue with a high degree of con- (SPECT) has been the cornerstone of nuclear medicine and today fidence. The imaging agents use target-specific biological it is widely used to detect molecular changes in cardiovascular, processes associated with the disease being assessed both at neurological and oncological diseases. While SPECT has been the cellular and subcellular levels within living organisms. available since the 1980s, advances in instrumentation hardware, The impact of molecular imaging has been on greater under- software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper. standing of integrative biology, earlier detection and charac- The biggest change in the last decade has been the fusion terization of disease, and evaluation of treatment in human of CT with SPECT, which has improved attenuation correction subjects [1–3].
    [Show full text]
  • Pharmacological Properties of GABAA- Receptors Containing Gamma1
    Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 Molecular PharmacologyThis article hasFast not Forward.been copyedited Published and formatted. on The November final version 7, may 2005 differ as from doi:10.1124/mol.105.017236 this version. MOLPHARM/2005/017236 Pharmacological properties of GABAA- receptors containing gamma1- subunits Khom S.1, Baburin I.1, Timin EN, Hohaus A., Sieghart W., Hering S. Downloaded from Department of Pharmacology and Toxicology, University of Vienna Center of Brain Research , Medical University of Vienna, Division of Biochemistry and molpharm.aspetjournals.org Molecular Biology at ASPET Journals on September 27, 2021 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Running Title: GABAA- receptors containing gamma1- subunits Corresponding author: Steffen Hering Department of Pharmacology and Toxicology University of Vienna Althanstrasse 14 Downloaded from A-1090 Vienna Telephone number: +43-1-4277-55301 Fax number: +43-1-4277-9553 molpharm.aspetjournals.org [email protected] Text pages: 29 at ASPET Journals on September 27, 2021 Tables: 2 Figures: 7 References: 26 Abstract: 236 words Introduction:575 words Discussion:1383 words 2 Molecular Pharmacology Fast Forward. Published on November 4, 2005 as DOI: 10.1124/mol.105.017236 This article has not been copyedited and formatted. The final version may differ from this version. MOLPHARM/2005/017236 Abstract GABAA receptors composed of α1, β2, γ1-subunits are expressed in only a few areas of the brain and thus represent interesting drug targets.
    [Show full text]
  • 1,4-Benzodiazepine: an Overview of Biological Properties
    Sci. Revs. Chem. Commun.: 5(1), 2015, 13-20 ISSN 2277-2669 1,4-BENZODIAZEPINE: AN OVERVIEW OF BIOLOGICAL PROPERTIES IRAM KHAN*, ANUPAMA and BHAWANI SINGHa Department of Chemistry, Banasthali University, BANASTHALI (Raj.) INDIA aDepartment of Pure & Applied Chemistry, University of Kota, KOTA (Raj.) INDIA (Received : 16.02.2015; Accepted : 02.03.2015) ABSTRACT The term benzodiazepine is the chemical name for the heterocyclic ring system, which is a fusion of benzene and diazepine ring systems. 1,4-benzodiazepine is related with a huge range of biological properties. These ring systems are incorporated into drugs used for AIDS, cancer, anti-viral treatment etc. 1,4-benzodiazepine derivatives are well established in the literature as important biologically active compounds. They have a long history of application in agrochemicals and pharmaceutical industry as herbicides and active pharmaceuticals. 1,4-benzodiazepine and their numerous derivatives have continued to capture the concentration of chemists since their existence in the biologically active materials have been known to produce additive effect on the bio-efficacy of the molecules. Key words: 1,4-benzodiazepine, anti-viral, bio-efficacy. INTRODUCTION History of benzodiazepines was started after the discovery of diazepam (Fig. 1) in 1955 by Leo Sternbach. From that day the research on 1,4- benzodiazepine nucleus is continue. There is a lots of drugs having 1,4-benzodiazepine nucleus. 1,4-Benzodiazepine nucleus containing drugs mostly used for the treatment of anxiety, but they also are useful in treating several other conditions in human. It is a most common prescribed drug for CNS disorders. Benzodiazepines affect a neurotransmitter chemical, gamma- aminobutyric acid (GABA), which is used by nerves to communicate with one another1.
    [Show full text]
  • Treatments for Spasticity and Pain in Multiple Sclerosis: a Systematic Review
    This is a repository copy of Treatments for spasticity and pain in multiple sclerosis: a systematic review . White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/1776/ Monograph: Beard, S.M., Hunn, A. and Wight, J. (2003) Treatments for spasticity and pain in multiple sclerosis: a systematic review. Technical Report. Gray Publishing , Tunbridge Wells. ISSN 1366-5278 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Health Technology Assessment 2003; Vol. 7: No. 40 Treatments for spasticity and pain in multiple sclerosis: a systematic review S Beard A Hunn J Wight Health Technology Assessment NHS R&D HTA Programme HTA HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.ncchta.org).
    [Show full text]
  • Physiological Roles of Endogenous Neurosteroids at Α2 Subunit-Containing GABAA Receptors
    Physiological roles of endogenous neurosteroids at α2 subunit-containing GABAA receptors Elizabeth Jane Durkin A thesis submitted to University College London for the degree of Doctor of Philosophy October 2012 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street London WC1E 6BT Declaration 2 Declaration I, Elizabeth Durkin, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis Abstract 3 Abstract Neurosteroids are important endogenous modulators of the major inhibitory neurotransmitter receptor in the brain, the γ-amino-butyric acid type A (GABAA) receptor. They are involved in numerous physiological processes, and are linked to several central nervous system disorders, including depression and anxiety. The neurosteroids allopregnanolone and allo-tetrahydro-deoxy-corticosterone (THDOC) have many effects in animal models (anxiolysis, analgesia, sedation, anticonvulsion, antidepressive), suggesting they could be useful therapeutic agents, for example in anxiety, stress and mood disorders. Neurosteroids potentiate GABA-activated currents by binding to a conserved site within α subunits. Potentiation can be eliminated by hydrophobic substitution of the α1Q241 residue (or equivalent in other α isoforms). Previous studies suggest that α2 subunits are key components in neural circuits affecting anxiety and depression, and that neurosteroids are endogenous anxiolytics. It is therefore possible that this anxiolysis occurs via potentiation at α2 subunit-containing receptors. To examine this hypothesis, α2Q241M knock-in mice were generated, and used to define the roles of α2 subunits in mediating effects of endogenous and injected neurosteroids. Biochemical and imaging analyses indicated that relative expression levels and localization of GABAA receptor α1-α5 subunits were unaffected, suggesting the knock- in had not caused any compensatory effects.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]